Nikkei Index May Rise as Investors Assess Tariff Developments

格隆汇2026/02/23 23:48

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Glonghui, February 24th｜As investors assess tariff developments, Japanese stocks may rise. Media reports citing informed sources stated that the Trump administration is considering imposing new national security tariffs on six industries. Previously, U.S. President Trump said over the weekend that he would raise a new global tariff rate to 15%, aiming to replace several tariffs that were ruled illegal by the Supreme Court last week. Nikkei index futures on the Singapore Exchange rose 0.2% to 56,770 points. The USD/JPY was quoted at 154.69 yen, compared to 154.66 yen in New York on Monday night. The Nikkei index fell 1.1% last Friday to 56,825.70 points. The Japanese market was closed on Monday due to a holiday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hulamin said independent non-executive director Paul Baloyi resigned, effective Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hulamin Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604350), on October 05, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/05 14:30

US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher

On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.

智通财经•2026/10/05 13:47